- In patients with Helicobacter pylori (H pylori)-associated chronic gastritis, the administration of H pylori eradication therapy was associated with increased high-density lipoprotein (HDL) levels.
- Low-density lipoprotein (LDL)/HDL ratio significantly decreased at post-eradication vs pre-eradication therapy.
Why this matters
- Finding suggests that H pylori eradication may prevent arteriosclerosis development by regulating serum lipid concentrations, especially the HDL levels.
- Study of 163 patients with H pylori-associated chronic gastritis (mean age, 56.7 years; mean follow-up duration, 514.7 days) who underwent the health screening examination between 2015-2017.
- Clinical parameters compared before and after H pylori eradication therapy.
- Funding: None.
- Post-eradication vs pre-eradication therapy was associated with significant increase in:
- weight (60.1±13.9 kg vs 59.6±13.8 kg; P=.001),
- body mass index (22.6±4.5 kg/m2 vs 22.4±4.5 kg/m2; P=.003),
- obesity index (2.7±20.5 vs 1.8±20.5; P=.005), and
- HDL (63.3±15.8 mg/dL vs 61.2±14.7 mg/dL; P<.01>
- Post-eradication vs pre-eradication therapy significantly decreased WBC (4989.2±1371.1×103/μL vs 5372.1±1359.4×103/μL; P<.001 and platelet count>3/μL vs 24.3 ±5.9×103/μL; P=.001).
- The LDL/HDL ratio was significantly decreased at post-eradication vs pre-eradication therapy (2.02±0.76 mg/dL vs 2.11±0.75 mg/dL; P<.01>
- No significant changes were observed in:
- total cholesterol (206.0±32.5 mg/dL vs 205.1±30.8 mg/dL),
- LDL (121.2±28.7 mg/dL vs 119.0±27.6 mg/dL),
- triglycerides (98.1±50.9 mg/dL vs 103.5±58.0 mg/dL), and
- red blood cells (461.4 ±38.2×106/μL vs 461.9 ±37.5×106/μL; P=.607).
- Retrospective and single-centre study.
- Small sample size.